Cargando…
HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer
Anaplastic thyroid carcinoma (ATC) and squamous thyroid carcinoma (STC) are both rare and advanced thyroid malignancies with a very poor prognosis and an average median survival time of 5 months and less than 20% of affected patients are alive 1 year after diagnosis. The clinical management of both...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359659/ https://www.ncbi.nlm.nih.gov/pubmed/30669676 http://dx.doi.org/10.3390/ijms20020454 |
_version_ | 1783392312906219520 |
---|---|
author | Lin, Ching-Ling Tsai, Ming-Lin Lin, Chun-Yu Hsu, Kai-Wen Hsieh, Wen-Shyang Chi, Wei-Ming Huang, Li-Chi Lee, Chia-Hwa |
author_facet | Lin, Ching-Ling Tsai, Ming-Lin Lin, Chun-Yu Hsu, Kai-Wen Hsieh, Wen-Shyang Chi, Wei-Ming Huang, Li-Chi Lee, Chia-Hwa |
author_sort | Lin, Ching-Ling |
collection | PubMed |
description | Anaplastic thyroid carcinoma (ATC) and squamous thyroid carcinoma (STC) are both rare and advanced thyroid malignancies with a very poor prognosis and an average median survival time of 5 months and less than 20% of affected patients are alive 1 year after diagnosis. The clinical management of both ATC and STC is very similar because they are not particularly responsive to radiotherapy and chemotherapy. This inspired us to explore a novel and effective clinically approved therapy for ATC treatment. Histone deacetylase inhibitor (HDACi) drugs are recently FDA-approved drug for malignancies, especially for blood cell cancers. Therefore, we investigated whether an HDACi drug acts as an effective anticancer drug for advanced thyroid cancers. Cell viability analysis of panobinostat treatment demonstrated a significant IC50 of 0.075 µM on SW579 STC cells. In addition, panobinostat exposure activated histone acetylation and triggered cell death mainly through cell cycle arrest and apoptosis-related protein activation. Using CRISPR/Cas9 to knock out HDAC1 and HDAC2 genes in SW579 cells, we observed that the histone acetylation level and cell cycle arrest were enhanced without any impact on cell growth. Furthermore, HDAC1 and HDAC2 double knockout (KO) cells showed dramatic cell apoptosis activation compared to HDAC1 and HDAC2 individual KO cells. This suggests expressional and biofunctional compensation between HDAC1 and HDAC2 on SW579 cells. This study provides strong evidence that panobinostat can potentially be used in the clinic of advanced thyroid cancer patients. |
format | Online Article Text |
id | pubmed-6359659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63596592019-02-06 HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer Lin, Ching-Ling Tsai, Ming-Lin Lin, Chun-Yu Hsu, Kai-Wen Hsieh, Wen-Shyang Chi, Wei-Ming Huang, Li-Chi Lee, Chia-Hwa Int J Mol Sci Article Anaplastic thyroid carcinoma (ATC) and squamous thyroid carcinoma (STC) are both rare and advanced thyroid malignancies with a very poor prognosis and an average median survival time of 5 months and less than 20% of affected patients are alive 1 year after diagnosis. The clinical management of both ATC and STC is very similar because they are not particularly responsive to radiotherapy and chemotherapy. This inspired us to explore a novel and effective clinically approved therapy for ATC treatment. Histone deacetylase inhibitor (HDACi) drugs are recently FDA-approved drug for malignancies, especially for blood cell cancers. Therefore, we investigated whether an HDACi drug acts as an effective anticancer drug for advanced thyroid cancers. Cell viability analysis of panobinostat treatment demonstrated a significant IC50 of 0.075 µM on SW579 STC cells. In addition, panobinostat exposure activated histone acetylation and triggered cell death mainly through cell cycle arrest and apoptosis-related protein activation. Using CRISPR/Cas9 to knock out HDAC1 and HDAC2 genes in SW579 cells, we observed that the histone acetylation level and cell cycle arrest were enhanced without any impact on cell growth. Furthermore, HDAC1 and HDAC2 double knockout (KO) cells showed dramatic cell apoptosis activation compared to HDAC1 and HDAC2 individual KO cells. This suggests expressional and biofunctional compensation between HDAC1 and HDAC2 on SW579 cells. This study provides strong evidence that panobinostat can potentially be used in the clinic of advanced thyroid cancer patients. MDPI 2019-01-21 /pmc/articles/PMC6359659/ /pubmed/30669676 http://dx.doi.org/10.3390/ijms20020454 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lin, Ching-Ling Tsai, Ming-Lin Lin, Chun-Yu Hsu, Kai-Wen Hsieh, Wen-Shyang Chi, Wei-Ming Huang, Li-Chi Lee, Chia-Hwa HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer |
title | HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer |
title_full | HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer |
title_fullStr | HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer |
title_full_unstemmed | HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer |
title_short | HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer |
title_sort | hdac1 and hdac2 double knockout triggers cell apoptosis in advanced thyroid cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359659/ https://www.ncbi.nlm.nih.gov/pubmed/30669676 http://dx.doi.org/10.3390/ijms20020454 |
work_keys_str_mv | AT linchingling hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT tsaiminglin hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT linchunyu hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT hsukaiwen hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT hsiehwenshyang hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT chiweiming hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT huanglichi hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer AT leechiahwa hdac1andhdac2doubleknockouttriggerscellapoptosisinadvancedthyroidcancer |